Breast screening linked to 60 percent lower risk of breast cancer death in first 10 years

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women, led in the UK by Queen Mary University of London.

The research, using data from Sweden, finds that women who chose to participate in an organised breast cancer screening programme had a 60 percent lower risk of dying from breast cancer within 10 years after diagnosis, and a 47 percent lower risk of dying from breast cancer within 20 years after diagnosis.

The authors say that this benefit occurs because screening detects cancers at an earlier stage, meaning that they respond much better to treatment.

The study was co-authored and funded by the American Cancer Society and appears in the American Cancer Society’s peer-review journal Cancer.

In the UK, mammography screening is offered to all women aged 50-70 through the NHS Breast Screening Programme, with participation rates averaging more than 70 per cent but varying dramatically across the country, with lower rates in poorer, inner-city areas.

“Recent improvements in treatments have led to reduced deaths from breast cancer. However, these new results demonstrate the vital role that screening also has to play, giving women a much greater benefit from modern treatments,” said senior author Professor Stephen Duffy, of Queen Mary University of London. “We need to ensure that participation in breast screening programmes improves, especially in socio-economically deprived areas.”

The study involved 52,438 women aged 40 to 69 years in the county of Dalarna, Sweden, during 39 years of the screening era (1977-2015). All patients received stage-specific treatment according to the latest national guidelines, irrespective of the mode of detection.

The investigators, led by Laszlo Tabar, of Falun Central Hospital in Sweden, used a new method to improve the evaluation of the impact of organised mammography screening on death from breast cancer, by calculating the annual incidence of breast cancers causing death within 10 years and within 20 years after breast cancer diagnosis.

The paper can be found here.

Table of Contents

YOU MAY BE INTERESTED IN

The nagging pain in Mia Sandino’s right knee set in in September 2018, and throughout her freshman year at the University of Washington, she tried to ignore it. “I was being a very naive and invincible-feeling 19-year-old,” Sandino told The Cancer Letter. “I didn’t put two and two together that this area of the knee that...

Rick Pazdur, MD, the newly appointed director for the Center for Drug Evaluation and Research at the FDA, has been described as “greyhound thin” as a result of his dedication to cycling and lifting weights in the gym each day and, for a long time, a vegetarian diet. I first met him when he was the director of the Office of Oncology Drug Products (ODP) within CDER, in 2009.
When it comes to fighting cancer today, collaboration is key. At a time when funding is uncertain, yet innovative breakthroughs are accelerating every day, it’s more important than ever for oncologists, scientists, academic researchers, and community physicians, to come together to share knowledge and gain insights about the forefront of cancer research.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login